Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
7.40
+0.61 (8.98%)
At close: Oct 15, 2026, 4:00 PM EDT
8.00
+0.60 (8.11%)
After-hours: Oct 15, 2026, 7:53 PM EDT
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year. That makes Kazia Therapeutics the 41,366th largest employer in the world and 6,388th in the United States.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$211,072
Profits / Employee
-$2,534,761
Market Cap
101.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 142 |
| Cibus | 118 |
| Foghorn Therapeutics | 106 |
| enGene Therapeutics | 82 |
| Vivani Medical | 42 |
| Milestone Pharmaceuticals | 38 |
| Unicycive Therapeutics | 22 |
| TuHURA Biosciences | 22 |
KZIA News
- 23 days ago - Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial - TheFly
- 23 days ago - Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders - PRNewsWire
- 5 weeks ago - Kazia Therapeutics announces first patient dosed in PNOC035 study - TheFly
- 5 weeks ago - Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer - PRNewsWire
- 6 weeks ago - Kazia Therapeutics price target raised to $40 from $34 at BTIG - TheFly
- 6 weeks ago - Kazia Therapeutics announces new preclinical, translational data on paxalisib - TheFly
- 6 weeks ago - Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy - PRNewsWire
- 6 weeks ago - Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer - TheFly